

Press Release

FOR IMMEDIATE RELEASE

23 JANUARY, 2026

Laurus Labs Announces 9M FY26 Results

Revenues at ₹ 5,001 Cr; EBITDA at ₹ 1,303 Cr, 26.1% margins

Hyderabad, January 23, 2026: Laurus Labs Ltd. (**Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028**), a leading research and development driven pharmaceutical and biotech company in India announces its Q3 & 9M FY26 results.

Financial Summary

[₹ Crore] except EPS amounts	3Q FY26	3Q FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
Revenues	1,778	1,415	26%	5,001	3,834	30%
Gross Margins	60.9%	56.9%	+4.0%	60.1%	55.8%	+4.3%
EBITDA	485	285	+70%	1,303	638	+104%
EBITDA Margins	27.3%	20.1%	+7.2%	26.1%	16.6%	+9.5%
PBT	327	131	+150%	821	172	+377%
Net Profit	252	92	+174%	610	125	+388%
EPS (Diluted)	4.7	1.7	+176%	11.3	2.3	+391%

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented:

“We are successfully executing on our strategy with continued advancements in important CDMO projects, ramping up new launches and strengthened leadership in antiretroviral in driving strong quarter and cumulative performance. These results confirm our Full year outlook of strong revenue growth and improving margin momentum.

Investments to continuously enhance service capability of Peptide technology platforms and ADC/Gene therapy is on track to meet current and future goals. We are confident that we are investing into interesting pipeline opportunities and these projects will continue to transform our Business portfolio and drive future growth with continued progress on ESG commitments.”

Corporate Office

Plot No.103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India

T +91 40 6659 4333, 2342 0500/501 F +91 40 6659 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

V V Ravi Kumar, Executive Director & Chief Financial Officer commented:

“We delivered another quarter of strong operational and financial performance, based on strong Generic business and continued demand upside in CDMO small molecule offerings. We have achieved revenues of ₹ 1,778 Cr, representing 26% growth and EBITDA of ₹ 485 Cr, representing 70% growth. The EBITDA margins stood at 27.3%, supported by continuing operating leverage.

Overall, we reported strong 9M performance. We achieved ₹ 5,001 Cr in revenues, representing 30% growth and EBITDA of ₹ 1,303 Cr, representing 104% growth, resulting in 26.1% EBITDA margins marking over 9% pts improvement over last year. Gross margins improved by over 4.3% pts to 60.1% due to favorable CDMO mix. Net Debt leverage decreased further to 1.2x EBITDA despite continuing CAPEX investments. We will continue investing behind high value business opportunities to drive near and long-term growth.”

Divisional Revenue Performance

[₹ Crore]	3Q FY26	3Q FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
CDMO	451	448	1%	1,491	1,044	43%
Small molecules	408	400	2%	1,372	913	50%
Bio	43	48	-10%	119	131	-9%
Generics	1,327	967	37%	3,510	2,790	26%
API	720	531	36%	1,974	1,752	13%
FDF	607	436	39%	1,536	1,038	48%
Total Revenues	1,778	1,415	26%	5,001	3,834	30%
ARV Revenues*	744	619	20%	2,124	1,756	21%

* Includes API and Formulation (FDF) combined revenues

Summary Highlights:

- Robust 9M performance; ₹ 5,001 Cr Revenues and 30% revenues growth
- Strong momentum in CDMO division, demand upside across complex chemistry platforms supported by robust performance in Generics division
- ₹ 1,303 Cr EBITDA with a margin of 26.1%, increased by 9.5% pts, due to improving operating leverage. Gross margins expansion of over 4.3% pts to 60.1% on better product mix.
- Q3 Revenues ₹ 1,778 Cr; +26% revenue growth, ₹ 485 Cr EBITDA; +70% growth resulted in a margin of 27.3%, Gross margins were at 60.9%
- Continued investment into manufacturing network expansion and niche capabilities with CAPEX at 15% of sales

Divisional Highlights:

CDMO – Small molecules

- CDMO business reported revenues of ₹ 1,372 Cr, during 9MFY26; increased by 50% from commercial supplies from existing relationships and mid to late stage projects ramp up
- Q3 Revenues of ₹ 408 Cr; increased by 2% Y/Y
- Advancing on commercial peptides manufacturing capability
- Pipeline momentum remained healthy: >110 Active pipeline projects
- Continued investment in large-scale capacity expansion at Vizag site

BIO – Large molecules

- Bio business reported revenues of ₹ 119 Cr, during 9MFY26; decreased by 9%. Growth impacted by Customer specific scale-up and scheduling issue
- Q3 Revenues of ₹ 43 Cr; decreased by 10% Y/Y
- Progressing discussion for longer term contracts, better visibility into FY27 and beyond
- Fermentation manufacturing site (Vizag) build up on track as planned - expect to commence operations by 2026 end

Generics

- Generics business reported revenues of ₹ 3,510 Cr, during 9MFY26, increased by 26% and further investing into capacity expansion
- Q3 Revenues of ₹ 1,327 Cr; increased by 37% Y/Y, primarily driven by higher ARV volumes and strong offtake in select molecules within developed markets
- Dedicated CMO oral dosage capacity commenced operations; full commercial production line starting from June 2026
- KRKA JV: FDF facility construction work going as per plan; Phase-1 expansion expected to be completed in mid 2027
- Product filings update:
 - DMF filings: Cumulatively, 92 DMFs filed till date
 - Developed market FDF filings: 4 product dossiers filed and a total of 5 approvals received (including Tentative approvals) in 9M. Cumulatively, 91 products filed till date

R&D and Other Highlights:

- Gene therapy/antibody-drug conjugate Process development lab operationalized in Hyderabad (India)
- Increased capital in JV, KRKA Pharma India, ₹49 Cr by Laurus and both partners together ₹100 Cr to support ongoing facility construction

Quality & ESG Highlights:

- We completed 109 Quality audits in 9M. Company has successfully passed audit inspections without critical findings
- Laurus achieved a 2025 S&P Global Corporate Sustainability Assessment (CSA) & ESG score of 81 out of 100 points, an impressive 10% pts increase over last year, reflecting our unwavering commitment to exceptional ESG practices

Earnings Conference Call

The company will organize a conference call on Friday, January 23, 2026 at 5:00 p.m. IST to discuss Q3 & 9M FY26 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
Hong Kong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	Click here to register

Transcript of the conference call will be available on the Company's website: www.lauruslabs.com

END

Media Relations

Karthik C
T +91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar
T +91 40 3980 4366
investorrelations@lauruslabs.com

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 7,042 people, including 2,632+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹5,554 crore in revenue in FY2025 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on [LinkedIn](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.